title: Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris.
abstract: The pharmacodynamics of intravenous bolus injections of 0.05, 0.10, 0.15, and 0.20 mg/kg of F(ab')2 fragments of the murine monoclonal antibody 7E3, 7E3-F(ab')2, directed against the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor of human platelets, were studied in groups of four patients with unstable angina pectoris. With 0.20 mg/kg, the template bleeding time prolonged from 6.3 +/- 1.9 (mean +/- SD) to greater than 30 min; it subsequently decreased to 13 +/- 7.8 min after 12 h and to 8.3 +/- 1.5 min after 24 h. The number of unblocked GPIIb/IIIa receptors (preinfusion value, 32,000 +/- 3,000 per platelet) decreased to 13 +/- 7% of the preinfusion value 1 h after infusion, and then increased to 33 +/- 10% at 12 h, 44 +/- 8% at 24 h and 67 +/- 7% at 72 h. The logarithm of the bleeding time was inversely proportional with the residual GPIIb/IIIa receptors (r = 0.73, P less than 0.0001). ADP-induced platelet aggregation (measured by changes in light transmittance in percent) decreased from 60 +/- 5% before infusion to 1.5 +/- 3% 1 h after infusion; it then increased to 29 +/- 3% after 24 h and 39 +/- 6% after 72 h. Platelet counts decreased by 16% at 1 h and returned to control values within 24 h. Proportionally smaller effects were seen at lower doses of 7E3-F(ab')2. Antibody injection did not induce spontaneous bleeding. Angina was not observed during the first 12 h when the bleeding time was significantly prolonged, but occurred in 6 of the 16 patients within the next 3 d. 2 of the 16 patients developed low titers of IgG antibodies specific for 7E3-F(ab')2. Thus 7E3-F(ab')2 induces dose-related inhibition of platelet function; at a dose of 0.20 mg/kg, it causes profound inhibition of platelet aggregation and prolongation of the bleeding time, but no spontaneous bleeding.
authors.affiliation: Cardiac Division, Massachusetts General Hospital, Boston 02114.
authors.forename: H K
authors.initials: HK
authors.lastname: Gold
authors.forename: L W
authors.initials: LW
authors.lastname: Gimple
authors.forename: T
authors.initials: T
authors.lastname: Yasuda
authors.forename: R C
authors.initials: RC
authors.lastname: Leinbach
authors.forename: W
authors.initials: W
authors.lastname: Werner
authors.forename: R
authors.initials: R
authors.lastname: Holt
authors.forename: R
authors.initials: R
authors.lastname: Jordan
authors.forename: H
authors.initials: H
authors.lastname: Berger
authors.forename: D
authors.initials: D
authors.lastname: Collen
authors.forename: B S
authors.initials: BS
authors.lastname: Coller
mesh_terms: D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000276:immunology; D004341:Drug Evaluation; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007167:Immunotherapy; D008875:Middle Aged; D010974:Platelet Aggregation; D010976:Platelet Count; D010979:Platelet Function Tests; D010980:Platelet Membrane Glycoproteins / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010980:Platelet Membrane Glycoproteins